TherapeuticsMD, Inc. (TXMD) stock

TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 12/3030% below fair value

$1.82−0.03 (-1.62%)

Close on Nov 12, 2026Market cap $21.07MP/E –Yield –

TherapeuticsMD EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

TherapeuticsMD's EV/EBITDA was 0.3× on Jan 31, 2024.

Period	Period end	Value	Change (pts)
2024	Jan 31, 2024	0.3×	+0.0
2023	Dec 29, 2023	0.3×	–

Parsed from the XBRL in TherapeuticsMD's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-50 reverse split on May 9, 2022
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing